BERGISCH GLADBACH, Germany, May 20 /PRNewswire/ -- Miltenyi Biotec announces the worldwide and exclusive release of Myelin Removal Beads. Myelin is a specialized membrane which ensheathes and insulates axons in the peripheral and central nervous system. During preparation of single-cell suspensions, myelin membrane fragments represent the major contaminant. "When dissociating adult neural tissue, usually less than 5 percent of the cell suspension consists of cells. The rest corresponds to cell debris", explains Dr. Rebecca Biloune, Product Manager for Neural Research Products at Miltenyi Biotec. "Removal of myelin leads to higher purity and recovery of target cells."
The novel product is suited for myelin removal from single-cell suspensions obtained from human, mouse, and rat tissues and is especially recommended prior to cell separations and cell stainings with Anti-Prominin-1 , CD133, Anti-PSA-NCAM, Anti-A2B5, or CD11b (microglia) MicroBeads and fluorochrome-conjugated antibodies, respectively.
"The beads work seamlessly with other MACS Technology products", adds Dr. Biloune. "Contaminating myelin fragments can be depleted either by manual protocols or by automated magnetic separations with the autoMACS(TM) Separator or the MACSQuant(TM) Analyzer." Myelin Removal Beads are exclusively available from Miltenyi Biotec. Detailed information is available at http://www.myelinremoval.com.
About Miltenyi Biotec
The company is one of the largest and most successful biotechnology companies in Germany. More than 1,100 employees worldwide develop, produce and sell products for biomedical research and clinical applications. The renowned MACS Technology for magnetic separation of cells has become a standard technology in research laboratories worldwide.
Contact Prof. Dr. Uwe Heinlein, Corporate Communications, Miltenyi Biotec GmbH Friedrich-Ebert-Str. 68, 51429 Bergisch Gladbach, Germany Phone +49-2204-8306-0, e-mail firstname.lastname@example.org http://www.miltenyibiotec.com
|SOURCE Miltenyi Biotec GmbH|
Copyright©2009 PR Newswire.
All rights reserved